Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
32.02
+0.36 (1.14%)
At close: Sep 30, 2026, 4:00 PM EDT
33.00
+0.98 (3.06%)
After-hours: Sep 30, 2026, 7:58 PM EDT
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| Iovance Biotherapeutics | 324.97M |
| CRISPR Therapeutics AG | 13.39M |
| CG Oncology | 6.23M |
COGT News
- 15 days ago - Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application - TheFly
- 15 days ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - GlobeNewsWire
- 21 days ago - Cogent Biosciences added to Analyst Focus List at JPMorgan - TheFly
- 6 weeks ago - Cogent Biosciences price target raised to $55 from $52 at Piper Sandler - TheFly
- 6 weeks ago - Cogent Biosciences price target raised to $52 from $45 at Guggenheim - TheFly
- 7 weeks ago - Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences Earnings release: Q2 2026 - Filings
- 7 weeks ago - Cogent Biosciences Quarterly report: Q2 2026 - Filings